These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31232771)

  • 1. Two New Drugs Approved for Multiple Sclerosis.
    Aschenbrenner DS
    Am J Nurs; 2019 Jul; 119(7):22-23. PubMed ID: 31232771
    [No Abstract]   [Full Text] [Related]  

  • 2. Trials and therapies in secondary progressive MS, simplified.
    Manouchehri N; Stüve O
    Nat Rev Neurol; 2019 Aug; 15(8):431-432. PubMed ID: 31285578
    [No Abstract]   [Full Text] [Related]  

  • 3. Cladribine for multiple sclerosis: review and current status.
    Sipe JC
    Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siponimod (Mayzent)--a new drug for multiple sclerosis.
    Med Lett Drugs Ther; 2019 May; 61(1571):70-72. PubMed ID: 31169805
    [No Abstract]   [Full Text] [Related]  

  • 5. Cladribine: limited evaluation in multiple sclerosis.
    Prescrire Int; 2011; 20(118):175. PubMed ID: 21751748
    [No Abstract]   [Full Text] [Related]  

  • 6. Cladribine: mechanisms and mysteries in multiple sclerosis.
    Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
    J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine as a therapeutic option in multiple sclerosis.
    Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.
    Song Y; Lao Y; Liang F; Li J; Jia B; Wang Z; Hui X; Lu Z; Zhou B; Luo W; Song B
    Medicine (Baltimore); 2019 Aug; 98(34):e15415. PubMed ID: 31441835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine.
    Biernacki T; Sandi D; Bencsik K; Vécsei L
    Mini Rev Med Chem; 2020; 20(4):269-285. PubMed ID: 31644403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siponimod Chips Away at Progressive MS.
    Longbrake EE; Hafler DA
    Cell; 2019 Dec; 179(7):1440. PubMed ID: 31951523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs may improve, complicate treatment for multiple sclerosis.
    Link H; Martin R
    Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513
    [No Abstract]   [Full Text] [Related]  

  • 12. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of cladribine treatment in multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
    Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J
    J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 16. [Emerging treatments for multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 18. Siponimod and CYP2C9 Allele Prevalence Among Blacks.
    Liu M; Obeng AO
    J Clin Pharmacol; 2020 Apr; 60(4):429-431. PubMed ID: 31701536
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 in Cladribine-treated patient with multiple sclerosis.
    Haham N; Vaknin-Dembinsky A
    J Neuroimmunol; 2021 Oct; 359():577690. PubMed ID: 34390951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].
    Grieb P; Stelmasiak Z
    Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.